Literature DB >> 17577049

Many new cancer drugs in the United Kingdom are facing negative NICE rulings.

Eric Low.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17577049     DOI： 10.1200/JCO.2007.11.4272

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Authors:  Steven D Pearson
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

2.  Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?

Authors:  Lesley Chim; Patrick J Kelly; Glenn Salkeld; Martin R Stockler
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.

Authors:  Vicki C Tse; Wai Tong Ng; Victor Lee; Anne W M Lee; Daniel T T Chua; June Chau; Sarah M McGhee
Journal:  BMC Cancer       Date:  2011-07-09       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.